Melanoma, NRAS-mutated

From - A Hematology Oncology Wiki
Jump to: navigation, search
Section editor
Elizabeth Buchbinder, MD
Dana-Farber Cancer Institute
Boston, MA


Note: these are biomarker-specific regimens, please see the main melanoma page for other regimens.

1 regimens on this page
1 variants on this page

Advanced or metastatic disease, TKI-naive

Binimetinib monotherapy

back to top


Study Evidence Comparator Comparative Efficacy
Ascierto et al. 2013 Phase II
Dummer et al. 2017 (NEMO) Phase III (E-switch-ooc) Dacarbazine Superior PFS


Continued indefinitely


  1. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56. Epub 2013 Feb 13. link to original article contains protocol PubMed
  2. NEMO: Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. Epub 2017 Mar 8. link to original article contains protocol PubMed